RFP 27-88872 Q&A Response.xlsx

XLSX spreadsheet 32 KB Posted

Attached to
RFP 27-88872 Toxicology ServicesBid Documents
Solicitation number
RFP 27-88872
Issued by
Marion County, Indiana

About this file

This is a Question and Answer Response document for RFP 27-88872, a toxicology services procurement issued by the Indiana Department of Administration (IDOA) on behalf of the Indiana Department of Health (IDOH) and the Indiana State Department of Toxicology (ISDT). The RFP solicits comprehensive toxicology and forensic toxicology testing services for ISO 17025 accredited laboratory analysis of blood, urine, and vitreous specimens across 366 analytes for postmortem testing and approximately 50 analytes for human performance/impaired driving investigations. Historical testing volumes are 307–539 monthly specimens for IDOH exclusively, with a minimum of 100 additional monthly samples anticipated for ISDT, all blood or serum specimens. The State may award contracts to one or more respondents, with separate volume allocations and responsibilities to be determined by IDOA during evaluation. Proposals are due November 30, 2026, at 3:00 PM Eastern Time, with a virtual pre-proposal conference scheduled for October 28, 2026. The contract term is four years from execution with two optional one-year renewals, extending to a potential six-year term. The awarded contractor must provide 99.5% monthly portal uptime, respond to helpdesk tickets within one business day, and achieve 95% specimen processing within 10 business days with a 15-business-day maximum turnaround for all work.

The cost proposal structure employs volume-based tiering for annual test volumes of 1–500, 501–1,000, and 1,001+ tests, with all-inclusive pricing that covers screening, confirmation, and directed confirmation testing; specimen collection supplies; shipping from all 92 county coroner offices; and associated costs. The State will evaluate proposals on 92 points, allocating 50 for Management Assessment and Quality, 30 for Price (normalized to lowest cost), and 5 points each for Buy Indiana Initiative certification, Indiana Veteran Owned Small Business (IVOSB) subcontracting goals (3%), and Indiana Small Business Program (INSBP) subcontracting goals (10%). Pricing must remain firm for 180 days from award. The current IDOH contract with AXIS expires June 30, 2028, and the new QPA is planned to commence January 2027 with services beginning thereafter. IDOH will transition to the new contract upon expiration of the existing agreement. The contractor must provide statewide specimen collection supplies including specific tube types and syringes, maintain electronic data interfaces with Indiana's Coroner Case Management System and Management Performance Hub (operational on day one of service), supply a PhD-level board-certified toxicologist at no additional cost, and deliver expert testimony and certified documentation services separately billable to IDOH and ISDT. Respondents must be registered with the Indiana Department of Administration and comply with Secretary of State registration requirements, with reference site visits and additional written clarification periods available during the evaluation process.

View the file

Other files

File Type Posted
Att_I_-_Pre-Proposal_Network_Form.pdf PDF
RFP 27-88872 - Toxicology Services.docx DOCX document
Att I - Pre-Proposal Network Form_NMS Labs.docx DOCX document
Att I - Pre-Proposal Network Form - Axon Advisors - IVOSB.docx DOCX document
Att I - Pre-Proposal Network Form 27-88872.docx DOCX document
Example Report_Redacted.pdf PDF
Att H - Reference Check Form.docx DOCX document
Att G - Q&A Template.xlsx XLSX spreadsheet
Att B - Sample Contract.docx DOCX document
Att I - Pre-Proposal Network Form.docx DOCX document
Att- K SOW (Toxicology).docx DOCX document
Att J - Attestation Form.docx DOCX document
Att B1 - IOT-IaaS.docx DOCX document
Att D - Cost Proposal.xlsx XLSX spreadsheet
Att E - Business Proposal.docx DOCX document
Att M-Infrastructure Overview.docx DOCX document
Att A1 - INSBP Commitment Form.docx DOCX document
Att A - IVOSB Commitment Form.docx DOCX document
Att F - Technical Proposal (Toxicology).docx DOCX document
Att B2 - IOT-PaaS.docx DOCX document
Att K1 - Full Analyte List.docx DOCX document
Att B3 - IOT-SaaS.docx DOCX document
RFP 27-88872 Main Document Tox.pdf PDF
Att L-Artificial Intelligence - Technical Proposal Questions.docx DOCX document
Show all 24

On GovTribe

Work with this file

  • Download the original file
  • Contacts named in this file
  • Similar government files
  • Ask GovTribe AI about this file

Text version

Question & Inquiry Form

Question and Answer Template
Attachment G
RFP 27-88872 Toxicology Services QPA
Please submit your questions in the form below (blue shaded area) by the date specified in RFP Section 1.23
Click the dropdown in the RFP Document Column to select topic.
No.RFP DocumentSection NumberPageTopicQuestionState's Responses
1Attachment K Statement of WorkIV.a — Project Management Plan; V — Transition3-4Commencement of IDOH and ISDT ServicesThe RFP combines toxicology services for ISDT and IDOH, which have different existing contract expiration dates. For purposes of pricing, implementation, and resource planning, please clarify the anticipated commencement date for services under each agency. Specifically, does the State anticipate that IDOH's statewide coroner toxicology program will transition to the contract awarded under this RFP before the current IDOH contract expires on June 30, 2028, or will services under the new contract commence upon expiration of the existing agreement?IDOH - not sure if you would like to terminate their contract if we got a cheaper price for this QPA or if you would transition into this QPA on expiration of 6/30/28, the QPA is planned to start in January. We plan on letting the current contract with AXIS expire and then use the QPA.
2Attachment K Statement of WorkI — Executive Summary1Single or Multiple Awards — Postmortem and Antemortem TestingSection 1.13 of the RFP indicates that the State may award contracts to one or more respondents. Does the State anticipate evaluating and awarding postmortem (IDOH) and antemortem/human performance (ISDT) testing separately, or will respondents be evaluated and selected for the combined scope?This is a decision that IDOA will make.
3Attachment K Statement of WorkI — Executive Summary1Single or Multiple Awards — Postmortem and Antemortem TestingSection 1.13 of the RFP indicates that the State may award contracts to one or more respondents. If multiple contractors are selected, how will responsibilities and testing volumes be allocated between agencies and among awarded contractors?The IDOH has a required list of drugs we require to be tested and would review those on our required list.
4Attachment K Statement of WorkI — Executive Summary1Historical and Anticipated Testing VolumesAttachment K identifies historical testing volumes of 307–539 specimens per month and a minimum of 100 ISDT samples. Please clarify whether the 307–539 monthly specimens represent IDOH coroner testing exclusively or the combined volume of both agencies.The 307 to 539 are exclusively IDOH.

Anticipated 100/month for ISDT.

5 Attachment K Statement of Work I — Executive Summary 1 Historical and Anticipated Testing Volumes Attachment K identifies historical testing volumes of 307–539 specimens per month and a minimum of 100 ISDT samples. Is the minimum of 100 ISDT samples an additional monthly volume, and can the State provide the anticipated ISDT specimen distribution by type and testing service? This QPA is to include the 307-507 for the IDOH and the 100 ISDT separately.

The 100 samples for ISDT will all be blood (mostly) or serum specimens.

6 Attachment K Statement of Work I — Executive Summary 1 Historical and Anticipated Testing Volumes Attachment K identifies historical testing volumes of 307–539 specimens per month and a minimum of 100 ISDT samples and indicates that the proposer must demonstrate capability. Is successful contract performance over the last several years with IDOH sufficient to demonstrate capability? It would be for the IDOH portion. Only the ISDT can answer for their portion of the QPA.

That would be sufficient for ISDT.

7Attachment D Cost Proposal TemplateRespondent Cost Proposal — Volume TiersN/A — Excel worksheetApplication of Volume-Based Pricing to Actual InvoicingAttachment D establishes pricing tiers for the first 500 tests, tests 501–1,000, and tests 1,001 and above. For actual contract administration and invoicing, will volume tiers be determined separately for each specimen/testing category or based on aggregate testing volume?This is a decision that IDOA will make.
8Attachment D Cost Proposal TemplateRespondent Cost Proposal — Volume TiersN/A — Excel worksheetApplication of Volume-Based Pricing to Actual InvoicingAttachment D establishes pricing tiers for the first 500 tests, tests 501–1,000, and tests 1,001 and above. Will volumes from IDOH and ISDT be combined when determining the applicable pricing tier?This is a decision that IDOA will make.
9Attachment D Cost Proposal TemplateRespondent Cost Proposal — Volume TiersN/A — Excel worksheetApplication of Volume-Based Pricing to Actual InvoicingAttachment D establishes pricing tiers for the first 500 tests, tests 501–1,000, and tests 1,001 and above. Are tier prices applied incrementally as each threshold is reached, or does reaching a higher tier establish the applicable price for all tests during that annual period?This is a decision that IDOA will make.
10Attachment D Cost Proposal TemplateRespondent Cost Proposal — Volume TiersN/A — Excel worksheetScreening and Confirmation Testing — Pricing DefinitionsAttachment K requires screening, confirmation, and directed confirmation testing, while Attachment D provides separate pricing components for blood, urine, vitreous, and Non-Screening Testing (Confirmation Testing). Please clarify which services are included in the blood, urine, and vitreous unit prices and which should be priced under the separate confirmation testing component.Blood, urine and vitreous are all the samples submitted by IDOH and require presumptive and confirmatory testing. ISDT must address their samples.

ISDT will send specimens for directed confirmations based on ISDT's screening results by LC/MS 11 Attachment D Cost Proposal Template Respondent Cost Proposal — Volume Tiers N/A — Excel worksheet Screening and Confirmation Testing — Pricing Definitions Attachment K requires screening, confirmation, and directed confirmation testing, while Attachment D provides separate pricing components for blood, urine, vitreous, and Non-Screening Testing (Confirmation Testing). Are confirmations performed as part of routine comprehensive toxicology testing included in the specimen prices, with the separate confirmation component reserved for individually requested or directed confirmations? For IDOH all tests prices must include presumptive and confirmatory. ISDT must address their samples.

ISDT will submit samples for directed confirmations. Most cases will be sent for 1-2 confirmations, but some cases may have more.

12Attachment D Cost Proposal TemplateRespondent Cost Proposal — Volume TiersN/A — Excel worksheetScreening and Confirmation Testing — Pricing DefinitionsAttachment K requires screening, confirmation, and directed confirmation testing, while Attachment D provides separate pricing components for blood, urine, vitreous, and Non-Screening Testing (Confirmation Testing). Are reflexed confirmations to be billed separately in addition to the specimen testing prices?This is a decision that IDOA will make.
13Attachment K Statement of WorkIII — Scope of Work1-2Expert Testimony and Related ServicesAttachment K requires expert testimony and certified documentation upon request, while Attachment D does not provide a separate pricing line for those services. Please clarify whether expert-witness services, including preparation, depositions, court appearances, and associated travel, are expected to be included in specimen testing prices or separately authorized and compensated by the requesting agency or other appropriate entity.For IDOH expert testimony can be provide separate from the sample testing cost.

For ISDT, expert testimony and documentation can be billed separately to ISDT. For historical purposes, FY26 included 17 certified documents and 5 testimonies for ~ 500 samples tested

14Attachment K Statement of WorkIII — Scope of Work1-2Expert Testimony and Related ServicesAttachment K requires expert testimony and certified documentation upon request, while Attachment D does not provide a separate pricing line for those services. While not directly impacting the budget of the IDOA, the costs of testimony and travel do impact the local budgets of the counties utilizing these services. Given the precedent of Smith v. Arizona, is there consideration of the financial and logistical benefit of a local company providing these services?This is a decision that IDOA will make.
14Attachment K Statement of WorkIII — Scope of Work1-2Expert Testimony and Related ServicesAttachment K requires expert testimony and certified documentation upon request, while Attachment D does not provide a separate pricing line for those services. Why would these services not be included in the evaluation of a cost proposal?IDOH and ISDT would expect a separate overall pricing for expert services.
15Attachment K Statement of WorkIII — Scope of Work1-2Existing State Data Interfaces and Integration RequirementsAttachment K requires secure electronic reporting and access to laboratory results but does not expressly address continuation of existing State data interfaces. Will the awarded contractor be required to maintain or establish electronic data interfaces with Indiana's Coroner Case Management System (CCMS) and Management Performance Hub (MPH)?The IDOH would require. It is up to the ISDT for their requirements.

ISDT will need the toxicology reports to be made available to ISDT electronically and to provide a monthly spreadsheet of all results.

16Attachment K Statement of WorkIII — Scope of Work1-2Existing State Data Interfaces and Integration RequirementsAttachment K requires secure electronic reporting and access to laboratory results but does not expressly address continuation of existing State data interfaces. If so (prior question), are these interfaces expected to be operational when IDOH services commence, and will the associated implementation and maintenance requirements be included in the State's technical evaluation?This must be operational on the day sample testing services begin for the IDOH.
17Attachment D Cost Proposal TemplateRespondent Cost Proposal — Years 1–5N/A — Excel worksheetPricing for Optional Renewal YearsSection 1.13 of the RFP provides for a four-year initial contract with two optional one-year renewals, for a potential six-year term. Attachment D requests pricing for Years 1 through 5, while its instructions establish that the evaluated Total Bid Amount covers the four-year initial contract period. Please clarify whether the fifth-year pricing is intended for the first optional renewal period and how pricing would be established for the second optional renewal year, should the State exercise that option.This is a decision that IDOA will make.
18Attachment K Statement of WorkMain RFP document: 1.6 — Question/Inquiry Process; 1.23 — Summary of MilestonesMain RFP document: 7–8, 13Additional Clarifications Following Published Q&AThe RFP establishes November 12, 2026, for publication of answers to vendor questions and November 30, 2026, for proposal submission. If published answers or subsequent amendments create additional material questions, does the State anticipate providing an additional written clarification period before proposals are due?There is a period for clarifying questions after scoring is held.
19Attachment D Cost Proposal TemplateWhole documentN/A — Excel worksheetRequired Testing – Defined Screening vs ConfirmationAttachment K1 implies only screening is required with the analytes listed. Attachment D – Cost Proposal provides space to submit pricing for Blood, Urine, and Vitreous testing inclusive of Shipping, and separate pricing for Confirmation Testing. These two pieces together imply that the requested testing setup requires screening to be charged, and confirmation tests to each be charged separately. Is that the intent?The IDOH expectations are a single price for each sample type to be all inclusive for presumptive and confirmatory, shipping and all supplies necessary for the coroner to collect the samples.

ISDT expectations are a single price for directed confirmations, including shipping and supplies (absorbent pads, plastic bags)

20Attachment D Cost Proposal TemplateWhole documentN/A — Excel worksheetRequired Testing – Defined Screening vs ConfirmationIf the answer to the prior question is 'YES', would the Office entertain a pricing structure that provides 1 set price for a case at a given price, with confirmation testing being included in that 1 price?Yes
21Attachment D Cost Proposal TemplateWhole documentN/A — Excel worksheetRequired Testing – Defined Screening vs ConfirmationIf the answer to the prior question is YES, how would Attachment D – Cost Proposal be submitted to indicate that type of testing?This is a decision that IDOA will make.
22Attachment D Cost Proposal TemplateWhole documentN/A — Excel worksheetRequired Testing – Defined Screening vs ConfirmationIf the intent is that all confirmation tests are billed separately, the math on Attachment D – Cost Proposal associated with Confirmation Testing is vastly underrepresented as it would be inclusive of blood, urine, and vitreous confirmations. The spreadsheet takes into account 1500 total Confirmation tests only for all matrices, and 4500 Screening Tests between the three matrices. Our experience with casework all throughout the United States (as well as currently with IDOH) is that the number of confirmations would exceed the number of screens performed at minimum. Should the Cost Proposal Template be adjusted?The IDOH expects a price estimate to include all drugs showing in the presumptive as positive and their related confirmatory test.
23Attachment K Statement of WorkMain RFP document: 1.6 — Question/Inquiry Process; 1.23 — Summary of MilestonesMain RFP document: 7–8, 13Additional Clarifications Following Published Q&ATo provide the best possible outcome for the State, it is required that potential submitters be provided clear and full responses to questions, given the complex nature of toxicological testing and the analyte specificity that is required by this RFP. If additional questions are raised as a result of this Q&A, or if answers are unclear, or if the question has been misunderstood and the response is a non-sequitur, what options do potential submitters have to ensure full and clear responses to these important questions?The should submit their questions to IDOA. IDOA will be responsible for officially getting the answers from the appropriate Agency.
24Attachment F Technical Proposal Template1.0 Mandatory Requirements1Mandatory Requirements - ClarificationThe 3 items in section 1.0 Mandatory Requirements are phrased as questions where respondents would provide an overview of what they provide, rather than a yes/no response. Typically, Mandatory Requirements within RFPs are yes/no responses and have a set list of requirements that are mandatory. As an example, Number 1 asks "What laboratory accreditations does your organization currently hold...", but does not list what accreditations might actually be mandatory. Likewise, Numbers 2 and 3 do not list any requirements that may or may not be mandatory, but are rather questions seeking what kind of services are offered. What is actually required in this section?The questions are to be answered as asked.
25Attachment F Technical Proposal Template1.0 Mandatory Requirements1Mandatory Requirements - ClarificationAre these answers to be judged and scored or simply noted as Pass/Fail as indicated on page 19 of 21 of the Main Document?The answers will be judge and scored.
26Attachment F Technical Proposal Template1.0 Mandatory Requirements1Mandatory Requirements - ClarificationIf Pass/Fail, what is considered a Pass and what is considered a Fail based on items 1-3 in Attachment F – Technical Proposal?In this step, proposals will be evaluated only against Criteria 1 to ensure that they adhere to Mandatory Requirements. Any proposals not meeting the Mandatory Requirements will be disqualified. The Mandatory Requirements are:

• Executive Summary and required content

• Attachment D Cost Proposal

• Attachment E Business Proposal

• Attachment F Technical Proposal, unaltered and complete with all requested supporting documents.

• Attachment J Attestation Form, complete with all requested supporting documents

• Infrastructure Overview

• AI Technical Proposal Questions 27 Attachment F Technical Proposal Template 3.0 Testing Capabilities & Laboratory 2 Technical Proposal - Clarification Section 3.0 Item 4 asks for turnaround time for screening tests, confirmation tests, and directed confirmation analyses individually. Is the expectation that screening results are provided in advance of confirmation results? For IDOH confirmatory test must be provided within 10 working days.

For ISDT 10 working days for one final report containing all confirmation results.

28Attachment F Technical Proposal Template3.0 Testing Capabilities & Laboratory2Technical Proposal - ClarificationThe nature of the testing requirements alluded to throughout the QPA would indicate that automatic/reflexed confirmation testing would occur. If that is the case, what is the need for screening specific turn-around time?Confirmatory tests are only required is the drug(s) are indicated in the presumptive test.
29Attachment F Technical Proposal Template3.0 Testing Capabilities & Laboratory2Technical Proposal - ClarificationWould it be acceptable to provide overall turnaround time for completion of casework?10 working days for the IDOH and ISDT.
30Attachment F Technical Proposal Template3.0 Testing Capabilities & Laboratory2Technical Proposal - ClarificationSection 3.0 Item 5 asks a question about measurement uncertainty and limits of detection. Given that these are required and reviewed as part of laboratory accreditation, why is it deemed necessary to ask this question?Would need IDOA to address that question.

(ISDT) I don't know what the question was, but ISDT needs the MU reported with each confirmation result and needs the limits of detection to be at least as low as ISDT LODs.

31 Attachment K Statement of Work VI. Compliance Requirements. Sample Handling and Testing Capabilities 6-7 Expansion of testing scope Bullet points 3 and 5 require approval for any additions to the analyte list provided. As part of normal business, adding newly relevant analytes occurs routinely to serve all clients. Would it be acceptable if analytes are added without approval so long as the additions do not accompany a cost increase of any kind? IDOH would encourage this.

Fine for ISDT.

32Attachment F Technical Proposal Template3.0, Question 22Evaluation of Analytical Scope and Forensic RelevanceIn evaluating a respondent's scope of toxicology testing, how will the State assess the relevance and usefulness of the laboratory's analytical capabilities to contemporary medicolegal death investigations (postmortem toxicology) and human performance forensic toxicology, including impaired-driving (DUI/DUID) investigations?This question just wants you to respond to the number of analytes you can test for and what methods, if any, you monitor to new drugs created by the so called "basement chemists".
33Attachment F Technical Proposal Template3.0, Question 22Evaluation of Analytical Scope and Forensic RelevanceSpecifically, will the evaluation consider the breadth of validated, routinely available testing for substances encountered in current forensic casework—including emerging synthetic opioids, nitazine, designer benzodiazepines, novel psychoactive substances, and other evolving drug classes—along with appropriate analytical sensitivity and specimen-specific capabilities?IDOH requires the drugs listed to be tested and just an overview of how you monitor for new drugs.
34Attachment F Technical Proposal Template3.0, Question 22Evaluation of Analytical Scope and Forensic RelevanceWill proposals be evaluated primarily on the total number of listed compounds, or will consideration also be given to the forensic relevance, currency, and demonstrated analytical capabilities of the testing offered?IDOH primary yardstick will be the number of drugs a vendor can test for from the required list.

ISDT just needs the drugs included in the analyte list.

35 Attachment K Statement of Work VI. Compliance Requirements. Sample Handling and Testing Capabilities 6 Recognition of Current and Emerging-Drug Testing Capabilities Attachment K1 identifies the State's analyte list; however, forensic toxicology testing continues to evolve as new drugs emerge and the substances encountered in medicolegal death investigations and impaired-driving cases change over time. How will the State evaluate respondents that routinely provide validated testing for additional compounds not included in Attachment K1, particularly newer drugs relevant to current Indiana casework? IDOH will rely on if and how a bidder monitors for new and emerging drugs.

ISDT does not frequently send for new and emerging drugs, but it is a consideration.

36Attachment K Statement of WorkVI. Compliance Requirements. Sample Handling and Testing Capabilities6Recognition of Current and Emerging-Drug Testing CapabilitiesWill these additional capabilities be considered in the technical evaluation, and will the State distinguish between analytes included in a laboratory's routine testing panel and those available only through separately requested or specialized testing?This is a decision that IDOA will make.
37Attachment K Statement of WorkVI. Compliance Requirements. Sample Handling and Testing Capabilities6Clarification of scope of testingBullet point 2 under this section indicates that all drugs on the agencies list (currently at 366) should be tested as part of the respondent's panel. We count 267 analytes listed on Attachment K1, although some of the analytes listed aren't actual analytes (such as the inclusion of "nan" as an analyte). Are there analytes missing from Attachment K1?The IDOH will only use the 366 named drugs listed on Appendix A. Full Analyte List should be disregarded.

ISDT only needs the ~50 analytes in our analyte list.

38 Attachment K Statement of Work VI. Compliance Requirements. Sample Handling and Testing Capabilities 6 Clarification of scope of testing Are all analytes required to be tested, or is there a minimum requirement/expectation of the QPA? The IDOH will only use the 366 named drugs listed on Appendix A. Full Analyte List should be disregarded. ISDT must also address this question from their perspective.

ISDT requires capability of all analytes on the analyte list of ~50 drugs

39Attachment K Statement of WorkVI. Compliance Requirements. Sample Handling and Testing Capabilities6Clarification of scope of testingHow will question 3.0 #2 on the technical proposal be evaluated?List those things that bidder could provide to certify test results.
40Attachment K Statement of WorkI — Executive Summary1Ability to fold existing ISDT testing needs into current IDOH contractWould folding the additional 100 specimens from IDOT into the existing IDOH contract serve the state better as it would get the value of legacy pricing and the scope which is beyond what's requested in the QAP?No, this will be a new procured Quantity Purchase Agreement.
41Attachment K Statement of WorkI — Executive Summary1Ability to fold existing ISDT testing needs into current IDOH contractIf the State does not believe that the current contract allows for use by ISDT, could the agreement be amended to allow it?No, this will be a new procured Quantity Purchase Agreement.
42Attachment B Sample Contract113Condition of PaymentWould the state accept the proposed language, “such reasonable satisfaction shall not be unreasonably withheld” and that the vendor would have an opportunity to mitigate any dissatisfaction of the client before the withholding of payment?Contract terms will be negotiated after award, however if you would like to include red lines in the sample contract for certain removal of terms, please let me know.
43Attachment B Sample Contract13 C.4Continuity of ServicesGiven the nature of the contract, it does not seem that this subsection is applicable, would the State consider removing this from the contract?Contract terms will be negotiated after award, however if you would like to include red lines in the sample contract for certain removal of terms, please let me know.
44Attachment B Sample Contract197Employment OptionGiven the nature of the contract, it does not seem that this subsection is applicable, may this section be deleted/omitted?Contract terms will be negotiated after award, however if you would like to include red lines in the sample contract for certain removal of terms, please let me know.
45Attachment B Sample Contract248IndemnificationIs the State open to/Will the state make this section mutual?Contract terms will be negotiated after award, however if you would like to include red lines in the sample contract for certain removal of terms, please let me know.
46Attachment B Sample Contract28 1. and 2.9Insurance (Commercial and Automobile)We carry $1 million per occurrence and $3 million in the aggregate. However, would our $5 million dollar umbrella policy suffice as coverage for those discrepancies? If so, can we insert exception language stating that the Umbrella Coverage will cure the threshold discrepancies?Yes, we can accept.
47Attachment B Sample Contract28 4.9Insurance (Fiduciary liability)Will a $3 million dollar policy be acceptable? If so, can the language be modified to reflect the exception?We would decide this upon contract negation however the State would be open.
48Attachment K Statement of WorkIV a.2Project Management / Communication planProject plan management states, "prior to implementing a new contract", vendor must submit a communication plan. Is there a specific time period requirement this must be submitted?2 weeks.
49Attachment K Statement of WorkVI6Specimen Collection Supplies & ServicesAttachment K requires the Contractor to provide statewide specimen-collection supplies, including syringes. Please provide the anticipated annual quantity and specifications for syringes and other required collection supplies (tubes, bottles, seals, boxes) that the Contractor will be expected to furnish. Would a PM box kit including Evacuated tube 16X100 10ML Gray, 60ml bottle, evidence bag, seal and box and DUID box kit including blood tubes, seals, needles be acceptable? And all other supplies not included in the kits will be provided separately as needed.For 2025 County coroners used 5,334 sample test kits shipped. Must Supply at least the following items: Grey Top Tubes- 6ml Blood.

Yellow Top Tubes-10ml Urine.

Clear Top- 6ml vitreous.

30ml Nalgene Bottle w/NaF:EDTA.

5mL syringe w/needle.

10mL syringe.

30 mL syringe.

18Gx1.5' Safety Needle.

16Gx4' Large Bore needle.

Postage paid mailers.

For ISDT (DUID), we only need evidence bag and absorbent sheets.

50 Attachment K Statement of Work VI 6 Specimen Collection Supplies & Services Would the state provide a itemized description or photograph of the specimen collection kits currently being used and the annual quantity? Grey Top Tubes- 6ml Blood; Yellow Top Tubes-10ml Urine; Clear Top- 6ml vitreous; 30ml Nalgene Bottle w/NaF:EDTA; 5mLsyringe w/needle; 10mL suringe; 30 mL syringe; 18Gx1.5' Safety Needle; 16Gx4' Large Bore needle.

N/A for ISDT.

51Attachment K Statement of WorkVI6Specimen Collection Supplies & Services / Result reportingTo ensure respondents fully understand and can comply with the State’s reporting requirements, would the State provide a redacted sample toxicology report representative of the current format for matrices (blood, urine, and vitreous).The IDOH will provide a redacted report for blood, urine and vitreous to IDOA and they will make available to anyone who requests.
52Attachment K Statement of WorkVI6Sample Handling and Testing Capabilities / 366 Compound ScopePlease clarify whether “test samples for all drugs on the agencies list” means that every submitted specimen must be tested for all 366 compounds, or whether the Contractor must maintain validated/verifiable testing capability for all 366 compounds.All samples submitted must have a presumptive test for all 366 drugs.
53Attachment K Statement of WorkVI6Sample Handling and Testing Capabilities / Specimen volumePlease provide the historical annual specimen volumes by matrix, including blood, urine, and vitreous, for the most recent available period.For calendar year 2025 tested Blood= 3,888; Urine= 407; Vitreous= 662

For ISDT, ~500 blood samples for FY26

54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
Attachment A IVOSB Commitment
Attachment B Sample Contract
Attachment B1 IOT - IaaS
Attachment B2 IOT - PaaS
Attachment B3 IOT - SaaS
Attachment D Cost Proposal Template
Attachment E Business Proposal Template
Attachment F Technical Proposal Template
Attachment H Reference Form
Attachment I Pre-Proposal Network Opportunities Form
Attachment J Attestation Form
Attachment K Statement of Work
AI Technical Proposal Questions
Infrastructure Overview

File details come from the government source that posted it. Updated .